Answers to

Frequently Asked Questions

for Patients Transitioning From Lyophilized (Powder) PROLASTIN®-C to PROLASTIN®-C LIQUID

The same therapy trusted by patients with alpha-1 and their doctors for more than 25 years in a convenient, ready-to-use liquid formulation

Now that PROLASTIN-C LIQUID is available, you may have some questions. The following includes answers to some common questions you may have right now. Take comfort in knowing that the PROLASTIN DIRECT® program will be there for you every step of the way as you transition from PROLASTIN-C powder to PROLASTIN-C LIQUID.

After reading this information, if you have additional questions, contact the PROLASTIN DIRECT® program toll free at 1-800-305-7881.

Please see Important Safety Information on the back cover, and see full Prescribing Information for PROLASTIN-C LIQUID at www.prolastin.com.
Frequently Asked Questions

Will my PROLASTIN DIRECT® program benefits, services, or support change?
No, with PROLASTIN®-C LIQUID, you will still receive the same ongoing, personalized support you have always received from the PROLASTIN DIRECT program. You will continue to work with your PROLASTIN DIRECT program Patient Service Coordinator, infusion nurse, and AlphaNet Coordinator.

Does PROLASTIN-C LIQUID work the same as PROLASTIN-C powder?
Yes, PROLASTIN-C LIQUID is the same medicine you have been receiving in a powder formulation. PROLASTIN-C LIQUID has been proven to effectively raise alpha1-antitrypsin protein levels in patients with alpha-1.

What are the side effects of PROLASTIN-C LIQUID?
The overall frequency of adverse events was similar between PROLASTIN-C LIQUID and PROLASTIN-C powder formulation, and no adverse events led to treatment withdrawal. The most common adverse reactions during clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

How do I obtain PROLASTIN-C LIQUID?
To transition to PROLASTIN-C LIQUID, you will need a new prescription. Contact Dohmen Life Science Services (Dohmen), the only specialty pharmacy that fills PROLASTIN-C LIQUID prescriptions, and they will happily handle the process for you.

Is PROLASTIN-C LIQUID still shipped and stored the same way?
PROLASTIN-C LIQUID continues to be shipped directly from Dohmen to the same address on file. It will continue to ship in the same packaging currently used to deliver your PROLASTIN-C. Store in your refrigerator at 36-46°F (2-8°C) for the period indicated by the expiration date on its label. Product may be stored at room temperatures not exceeding 77°F (25°C) for up to one month, after which the product must be used or immediately discarded. Do not freeze.
Frequently Asked Questions

Does PROLASTIN-C LIQUID need to be mixed?
No, PROLASTIN-C LIQUID is ready to infuse. That means it no longer needs to be mixed by you or your infusion nurse before your infusion, which will shorten your preparation time.

Does the liquid mean more volume for my infusions?
No, your infusion volume will be the same as your current PROLASTIN-C.

Does the product include latex?
No, the PROLASTIN-C LIQUID vial stopper is latex free.

Does the liquid take longer to infuse?
No, the average PROLASTIN-C LIQUID infusion takes about 15 minutes when given at the recommended rate of 0.08 mL/kg/min—the same as PROLASTIN-C powder, but without the added mixing time.

Is PROLASTIN-C LIQUID covered by my insurance?
Insurance coverage of PROLASTIN-C LIQUID is typically the same as PROLASTIN-C, but every insurance plan is different. Once your prescription has been updated, the PROLASTIN DIRECT program insurance specialists will automatically verify your specific coverage for PROLASTIN-C LIQUID.

If your health insurance plan doesn’t cover PROLASTIN-C LIQUID today, the insurance specialists at PROLASTIN DIRECT will continue to monitor your health insurance plan and keep you informed as they coordinate the monthly delivery of your PROLASTIN-C powder formulation.

After reading this information, if you have additional questions, contact the PROLASTIN DIRECT program toll free at 1-800-305-7881.

Please see Important Safety Information on the back cover, and see full Prescribing Information for PROLASTIN-C LIQUID at www.prolastin.com.
Important Safety Information

PROLASTIN®-C LIQUID is an alpha₁-proteinase inhibitor (human) (alpha₁-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha₁-PI (alpha₁-antitrypsin deficiency).

Limitations of Use

• The effect of augmentation therapy with any alpha₁-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha₁-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials

• Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available

• PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha₁-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha₁-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID at www.prolastin.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.